Studies Pinpoint Which Patients Can Skip Cancer Treatments

 FILE - This undated fluorescence-colored microscope image made available by the National Institutes of Health in September 2016 shows a culture of human breast cancer cells. A study discussed at the 2022 meeting of the American Society of Clinical Oncology suggests some low-risk breast cancer patients can omit radiation after lumpectomy. (Ewa Krawczyk/National Cancer Institute via AP) THE ASSOCIATED PRESS


By CARLA K. JOHNSON, AP Medical Writer


After surgery, some cancer patients can safely skip radiation or chemotherapy, according to two studies exploring shorter, gentler cancer care.


Recommended Videos

Powered by AnyClip

Study Raises Questions About Colon Cancer Screenings Later in Life

41.4K

Play Video

Study Raises Questions About Colon Cancer Screenings Later in LifeNOW PLAYING

‘We are really helpless’: Sri Lanka crisis leaves cancer patients without vital medicine

Johnson & Johnson Cancer Lawsuits Reveal History of Human Experimentation on Black Inmates

These 7 Conditions Drastically Impact Your Risk for Severe COVID-19

Pfizer breast cancer drug fails late-stage test

Researchers are looking for ways to precisely predict which cancer patients can avoid unneeded treatment to cut down on harmful side effects and unnecessary costs.


One new study used a blood test to determine which colon cancer patients could skip chemotherapy after surgery. Another suggests some low-risk breast cancer patients can omit radiation after lumpectomy.


The research was discussed at the annual meeting of the American Society of Clinical Oncology, which wrapped up Tuesday in Chicago. The colon cancer study, funded by the Australian and U.S. governments and nonprofit groups, was published Saturday by the New England Journal of Medicine.


Political Cartoons


View All 519 Images


The findings could allow doctors to “focus on the patients we think would truly benefit from chemotherapy and avoid the side effects for patients for whom it’s likely unnecessary,” said Dr. Stacey Cohen of Fred Hutchinson Cancer Center in Seattle, who reviewed the colon cancer findings and was not involved in the research.


COLON CANCER


Many colon cancer patients are given chemotherapy after surgery, even though they may be cured. The drugs can come with side effects such as nausea, anemia and memory problems.


But pinpointing which patients might not need further treatment has been tricky. Scientists studied whether a blood test could help doctors make the call.


The study involved 455 patients who had surgery because cancer had spread into the colon wall. After surgery, one group received a blood test, customized to their tumor’s genetic profile, to detect any remaining bits of cancer DNA.


Their care was guided by the blood test: If it showed no signs of remaining cancer, the patients did not get chemotherapy. Meanwhile, doctors made chemo decisions for the rest of the patients in the usual way, guided by analysis of the tumor and nearby tissue.



Fewer patients in the blood test group got chemo — 15% vs. 28%. But about 93% of both groups were still free of cancer after two years. In other words, the blood test group fared equally well with less chemotherapy.


“In patients where cancer DNA is not detected after surgery, the chance of cancer relapse is very low, suggesting that chemotherapy is very unlikely to benefit these patients,” said Dr. Jeanne Tie of the Peter MacCallum Cancer Centre in Melbourne, Australia, who led the research.


Skipping chemo makes “a big difference in a person’s quality of life if that can be done without having to put them at jeopardy for recurrence,” said ASCO president Dr. Everett Vokes, who specializes in head and neck and lung cancer at University of Chicago Medicine.


BREAST CANCER


The other study followed 500 older women with a common form of early-stage breast cancer and low levels of a protein known as Ki67, a marker for fast-growing cancer.


After surgery, the women took hormone-blocking pills, a standard treatment for this type of cancer, but they did not get radiation treatment.


After five years, 10 of the women saw cancer return in the same breast, and there was one breast cancer death. There was no comparison group, but researchers said the results compare favorably to historical data for similar patients who had radiation.


“We estimate the benefits of radiation would be very small in this population compared to the side effects,” said Dr. Timothy Whelan of McMaster University in Hamilton, Ontario, who led the study, which was supported by the Canadian Breast Cancer Foundation and the Canadian Cancer Society.


Radiation can cause skin problems, fatigue and, less commonly, long-term heart problems and second cancers.


The study is a “feel-good” message for patients with low-risk tumors and will help doctors understand which of their patients they “can comfortably, with confidence” omit radiation, said Dr. Deborah Axelrod of NYU Langone Health, who was not involved in the research.


___


The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.


Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Comments

Popular posts from this blog

WEDNESDAY, June 8, 2022 (HealthDay News) -- Even after vaccination, living with HIV ups the odds for COVID infection, new research shows. Recommended Videos Powered by AnyClip Pfizer’s 3-Dose Vaccine 80% Effective Against Omicron Infection for Youngest Children 1.4K Play Video Pfizer’s 3-Dose Vaccine 80% Effective Against Omicron Infection for Youngest ChildrenNOW PLAYING This Is How a COVID-19 Infection Could Damage Your Brain Top 5 Symptoms of ‘Breakthrough’ COVID-19 White House Warns COVID-19 Cases Could Double Late This Year Are Boosted Americans More Likely To Catch COVID-19? The study found that vaccinated people living with HIV have a 28% higher risk of developing a "breakthrough" COVID infection compared to those who don't have the AIDS-causing virus. That’s the bad news. But there's good news, too: The overall risk for COVID infection among people vaccinated with at least the two primary doses remains low, regardless of their HIV status. “We thought we might see an increase in the risk of breakthrough in people with HIV because of the impact of HIV on the immune system and the role of the immune system in responding to vaccination and infection from a virus like SARS-Cov-2," reasoned study author Keri Althoff. So, the researchers weren't surprised to find "that about 4 in 100 people with HIV experience a breakthrough, compared to 3 in 100 people without HIV," said Althoff, an associate professor in the Johns Hopkins School of Public Health epidemiology department. But it was a relief, she said, to see that nine months after vaccination, "the rate and risk of breakthrough is low among vaccinated people with and without HIV" -- around 4% in each group. Her team analyzed data on nearly 114,000 COVID-vaccinated men and women, of whom 33,000 had HIV. Most were 55 years and up, 70% were white, and more than 9 in 10 were men. The authors focused on COVID risk during the latter half of 2021, when the more contagious Omicron variant emerged. Althoff noted that breakthrough infections were higher across the board -- regardless of HIV status -- in December, when Omicron became the dominant strain. Beyond identifying the 28% higher risk for a breakthrough infection among those with HIV, the researchers noted that certain individuals with HIV faced a higher infection risk than others. They included people under age 45, compared with those between 45 and 54. Risk was also higher among those who had not received a third (or booster) dose, and those with a prior infection. Risk of breakthrough infection in folks with HIV also increased as their T-cell counts dropped. According to the U.S. National Library of Medicine, T-cells are critical infection-fighting white blood cells which are typically attacked by HIV. (When an HIV patient's T-cell count falls to an extremely low level, it is often a sign of transition to full-blown AIDS.) Althoff said she and her colleagues "hypothesize that HIV-induced immune dysfunction may be playing a role in vulnerability to breakthrough COVID-19 illness." For that reason, boosters may be critical for such patients, she said. Currently, Althoff pointed out, third-dose boosters are recommended for those whose HIV is either untreated or advanced. "To increase protection against breakthrough infections, all people with HIV may need an additional dose in their primary series," she noted. That thought was echoed by Dr. Joel Blankson, a professor of medicine at Johns Hopkins Medicine, who was not part of the study. Because the study showed a decrease in breakthrough infections in patients who had received a third vaccine dose, "it is important that people living with HIV get a booster dose when they are eligible," Blankson said. The U.S. Centers for Disease Control and Prevention has COVID vaccine guidelines here. Additional research by Althoff's team suggests that hospitalization risk for breakthrough cases is higher among HIV-positive people compared to those without HIV. (Those findings are still under peer review and are not yet published.) Her advice to those with HIV: "Get vaccinated. Get boosted. Keep living your life and scale up and down your mitigation strategies -- mask-wearing, attending indoor gatherings, etc. -- based on the amount of COVID-19 transmitting in your community, and your personal health status." Dr. Thomas Gut is associate chair of medicine at the Zucker School of Medicine at Hofstra/Northwell in New York City. "The HIV-linked risk of reinfection is somewhat expected," said Gut, who had no role in the study. "In many other infectious diseases besides COVID, it's been known that patients with HIV do tend to have higher risk of both getting sick and having poorer outcomes." But patients with HIV "that have strong immune cell counts have traditionally been known to be better protected from infections compared to those with low immune system counts," he added. "It appears that COVID reinfection risk follows this same pattern." Therefore, Gut said, it is important to keep HIV infection under control as best as possible. The findings are in the June 7 issue of JAMA Network Open. More information There's more on HIV status and COVID-19 at HIV.gov. SOURCES: Keri N. Althoff, PhD, MPH, associate professor, epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore; Joel N. Blankson, MD, PhD, professor, medicine, Johns Hopkins Medicine, Baltimore; Thomas Gut, DO, associate chair, medicine, and director, ambulatory care services, Zucker School of Medicine at Hofstra/Northwell, Staten Island, N.Y.; JAMA Network Open, June 7, 2022 Copyright © 2022 HealthDay. All rights reserved.

Experts Urge Germany's Govt to Prepare for Fall COVID Wave

New Vaccine May Be Option for Troops With Religious Concerns